Clinical Trial Update: Nimotuzumab Plus Docetaxel and Capecitabine Versus Docetaxel and Capecitabine in the Treatment of Breast Cancer Patients [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update comparing nimotuzumab plus docetaxel and capecitabine versus docetaxel and capecitabine in breast cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Nimotuzumab (nimotuzumab)
• Taxotere (docetaxel)
• Xeloda (capecitabine)

Snippet

Sponsor: Chinese Academy of Medical Sciences | Conditions: Breast Cancer | Phase 2 | Status: UNKNOWN